Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data
-
By
-
Huiyi Deng
-
Wujiang Lai
-
Ying Xiang
-
Zewen Wang
-
Jiemei Liang
-
Yiwen Zhang
-
Jiale Liang
-
July 7, 2026
-
Clinical Scorecard: Evaluating the Safety Profile of Etomidate: Insights from Real-World Data Beyond Adrenal Suppression
At a Glance
| Category | Detail |
|---|
| Condition | Etomidate Adverse Drug Reactions |
| Key Mechanisms | Inhibition of 11β-hydroxylase affecting adrenal cortisol synthesis |
| Target Population | Patients receiving etomidate for anesthesia induction |
| Care Setting | Critical care and surgical settings |
Key Highlights
- 318 adverse drug reactions (ADRs) identified from FAERS database
- Novel ADRs include cardiac arrest, seizure, drug abuse, hypokalaemia, and bruxism
- Significant association with cardiac disorders and endocrine disorders
Guideline-Based Recommendations
Diagnosis
- Monitor for known and novel adverse drug reactions associated with etomidate
Management
- Implement strategies to mitigate risks in clinical practice
Monitoring & Follow-up
- Continuous post-marketing surveillance for long-term safety profile
Risks
- Potential for adrenal suppression and other adverse effects
Patient & Prescribing Data
Patients undergoing procedures requiring anesthesia
Awareness of potential adverse effects beyond adrenal suppression is crucial
Clinical Best Practices
- Heightened clinical vigilance for adverse reactions
- Regular updates of drug safety profiles
Related Resources & Content
